PET/CT for Trop2 ADC Response Evaluation Cancers

Summary

To evaluate whether serial 68Ga-MY6349 PET/CT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in breast cancer patients.

Eligibility

Inclusion Criteria:

* adult patients (aged 18 years or order)
* histologically or cytologically confirmed metastatic breast cancer previously treated with systemic therapy, supported by imaging (e.g., MRI, CT), tumor markers, or pathology reports
* presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1
* willingness to undergo serial 68Ga-MY6349 PET/CT scans before and during Trop2-ADC therapy
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
* Ability to provide written informed consent and, where applicable, assent in accordance with the requirements of the Clinical Research Ethics Committee

Exclusion Criteria:

* Evidence of significantly impaired hepatic or renal function
* Estimated life expectancy of less than 3 months

Conditions4

Browse More Trials